Hansoh Pharma's Furulium (PEGylated Losenatide) Accelerates Diabetic Wound Healing via Dual Mechanisms, Study Published in International Journal of Molecular Sciences

Recently, the research results on the impact and potential mechanisms of Hansoh Pharma's glucagon-like peptide-1 receptor agonist (GLP-1RA) weekly formulation, pegylated losenatide (brand name: Fulaimei), on diabetic wound healing were published in the International Journal of Molecular Sciences (INT J MOL SCI). This study revealed for the first time that Fulaimei accelerates diabetic wound healing through a dual mechanism—systemic anti-inflammatory regulation and repair of endothelial progenitor cell (EPC) function—thus providing a new strategy for the treatment of chronic diabetic wounds.

Diabetes is one of the leading causes of death and disability worldwide, with its vascular complications (such as delayed chronic wound healing) posing significant challenges in clinical treatment. The mechanisms underlying impaired wound healing in diabetes are complex, involving chronic inflammation, insufficient angiogenesis, dysfunction of endothelial progenitor cells (EPCs, the precursor cells of vascular endothelial cells), and mitochondrial oxidative stress. With the rising prevalence of diabetes, identifying effective strategies for wound prevention and treatment has become particularly urgent.

In recent years, GLP-1RA has attracted much attention due to its dual effects of lowering blood sugar and providing cardiovascular protection. A research team from Peking Union Medical College Hospital systematically evaluated the impact of Fulaimei on diabetic wound healing and its potential mechanisms through in vivo and in vitro experiments. The study used mice to establish a wound model and compared the wound healing conditions among diabetic mice treated with Fulaimei (diabetic treatment group), untreated diabetic mice (diabetic non-treatment group), and normal mice (control group). Additionally, the effect of Fulaimei on EPCs function was assessed through in vitro experiments. The study found that Fulaimei has the effects of improving metabolic disorders, accelerating wound healing, regulating systemic inflammation, and restoring EPCs function.

Previous in vitro studies have shown that Loxenatide can ameliorate EPCs injury and mitochondrial dysfunction through the SIRT3/Foxo3 signaling pathway. The first large-scale real-world study (FLYING) on GLP-1RA cardiovascular outcomes in the Chinese population, published in MedComm (IF: 10.7), clinically demonstrated that Loxenatide can reduce the risk of cardiovascular events in patients with type 2 diabetes.

This study provides theoretical support for the use of Fulaimi in the treatment of diabetic vascular complications, offers a new strategy for the treatment of chronic diabetic wounds, and expands the clinical application prospects of GLP-1RA, such as for the treatment of other diseases related to mitochondrial dysfunction. Future research will further explore its efficacy in humans and molecular regulatory networks.

The study was jointly supported by multiple fund projects, including the Senmei China Diabetes Research Fund.